Article
Avella Specialty Pharmacy today announced it has been identified as one of a select group of specialty pharmacies to supply Tarceva (erlotinib).
Avella Specialty Pharmacy today announced it has been identified as one of a select group of specialty pharmacies to supply Tarceva (Erlotinib). Effective July 1, Genentech, the manufacturer of Tarceva, will shift distribution of the drug to a limited network of select specialty pharmacies to better align distribution of the medication with similar specialty products and to help provide appropriate support for oncology patients on Tarceva therapy.
“Avella is proud to continue to have access to Tarceva. Being included in such an elite group of suppliers is a testament to our business model in the oral oncology market. Manufacturers like Genentech recognize Avella’s ability to serve patients in all 50 states and to provide high-touch patient services and reliable product data to ensure maximum drug effectiveness,” stated Leslie Yendro, RN, VP, Business Development of Avella.
Patients currently taking Tarceva will need to have their prescriptions filled by a pharmacy in the limited distribution network. Oncology referral forms can be downloaded at www.Avella.com/forms.
Specialty pharmacies play a key role in providing patients with complex medical conditions access to medications and in monitoring those patients to ensure correct usage. Working as a key component of the healthcare system, Avella collaborates with both providers and patients to offer unique solutions to their challenges. More information about Avella and its specialty services can be found at www.avella.com.
###
About Avella Specialty Pharmacy
Headquartered in Phoenix, Arizona, Avella Specialty Pharmacy (formerly operating as The Apothecary Shops) is a National Accredited Specialty Pharmacy, providing individualized care and support to patients since 1996. Avella's clinical pharmacists and staff members are experts in managing complex disease states and providing compassionate care. The company offers a nationwide distribution service to complement its retail locations. Avella reached 1,064th on Inc. magazine's list of the 5,000 fastest-growing private companies in the country, up more than 500 places from 2011. In addition, The Arizona Corporate Excellence Awards has named Avella as the fastest-growing private company based in the state. For more information, please visit Avella.com.
SOURCE: Avella
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa